10:16 AM EDT, 05/02/2024 (MT Newswires) -- Blueprint Medicines ( BPMC ) shares were up about 13% in recent trading on Thursday, after the company reported Q1 earnings against analysts' expectations of a loss.

The company reported Q1 net income of $1.40 per diluted share, compared with a per-share loss of $2.15 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.65 per share.

Revenue for the quarter ended March 31 was $96.1 million, up from $63.3 million a year earlier.

Analysts surveyed by Capital IQ expected $81.6 million.

Price: 109.54, Change: +14.68, Percent Change: +15.48